<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="32011">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02689934</url>
  </required_header>
  <id_info>
    <org_study_id>PROBIOTICO - BB536</org_study_id>
    <nct_id>NCT02689934</nct_id>
  </id_info>
  <brief_title>Efficacy of a Red Yeast Rice Based Nutraceutical Plus Probiotic in Patients With Moderate Hypercholesterolemia</brief_title>
  <official_title>Efficacy of Red Yeast Rice Based Nutraceutical (Monacolin K 10 mg/Dose) Plus Probiotic (Bifidobacterium Longum BB536 ®) in Patients With Moderate Hypercholesterolemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefarmaco OTC SpA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefarmaco OTC SpA</source>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy of a
      red yeast rice based nutraceutical (monacolin K 10 mg/dose) plus probiotic (Bifidobacterium
      longum BB536 ®), versus placebo, in patients with moderate hypercholesterolemia, in terms of
      improvement of the lipid profile and cardiovascular risk.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
    <masking_description>Double-blind (subjects, investigators)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in LDL-C From Baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent change from baseline in LDL-C after 12 weeks of treatment in patients with moderate hypercholesterolemia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of Lactoflorene colesterolo (Incidence of treatment-related adverse events)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Incidence of treatment-related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Other Lipids (non HDL-C, TG, HDL-C) and Apolipoproteins</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Vital Signs</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Lactoflorene colesterolo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Red Yeast Rice titrated in 10 mg monacolin K per daily dose plus Bifidobacterium longum 50 mg, powder form, 1 packet per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Lactoflorene colesterolo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo, powder form, 1 packet per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactoflorene colesterolo</intervention_name>
    <description>1.8 g + 1.8 g once a day per os</description>
    <arm_group_label>Lactoflorene colesterolo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo lactoflorene colesterolo</intervention_name>
    <description>1.8 g + 1.8 g once a day per os</description>
    <arm_group_label>Placebo Lactoflorene colesterolo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 ≤ men or women ≤ 70

          -  men or female. Female must be postmenopausal or surgically sterile

          -  130 mg/dl ≤ LDL-C ≤ 200 mg/dl

          -  patients in primary cardiovascular prevention

        Exclusion Criteria:

          -  pregnancy and lactating

          -  patients with chronic diseases

          -  patients with serious hepatic diseases

          -  patients with serious renal diseases

          -  patients with thyroid diseases

          -  diabetes mellitus or glycemia &gt;126 mg/dl

          -  uncontrolled or severe hypertension

          -  obesity(BMI&gt;30)

          -  smoking status

          -  drug or nutraceutical that can interfere with the experimental treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuliana G Mombelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ASST Grande Ospedale Metropolitano Niguarda Cà Granda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Dislipidemie Dip. Cardiotoracovasc ASST Grande Ospedale Metropolitano Niguarda Cà Granda</name>
      <address>
        <city>Milano</city>
        <state>Mi</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 1, 2017</lastchanged_date>
  <firstreceived_date>February 9, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypercholesterolemia</keyword>
  <keyword>bifidobacterium longum BB536</keyword>
  <keyword>red yeast rice</keyword>
  <keyword>monacolin K</keyword>
  <keyword>lactoflorene colesterolo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Red yeast rice</mesh_term>
    <mesh_term>Lovastatin</mesh_term>
    <mesh_term>L 647318</mesh_term>
    <mesh_term>Dihydromevinolin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
